Apnex secures $16.1m in series A:
This article was originally published in Clinica
Minneapolis, Minnesota-based Apnex Medical, a subsidiary of Prospex Medical, will finance the initiation of clinical studies of its implantable technology for the treatment of obstructive sleep apnea with $16.1m of private funding. Domain Associates, New Enterprise Associates, Polaris Venture Partners and Michael Berman, current active chairman of Apnex and co-founder of Prospex, all participated in the series A financing. Obstructive sleep apnea is the most significant form of a condition that causes restricted breathing during sleep. Sleep apnea affects an estimated 18 million Americans, according to the American Lung Association.